284.14
4.89 (1.75%)
| 前收盘价格 | 279.25 |
| 收盘价格 | 278.83 |
| 成交量 | 25,465 |
| 平均成交量 (3个月) | 297,610 |
| 市值 | 7,672,458,752 |
| 市盈率 (P/E TTM) | 10.21 |
| 预期市盈率 (P/E Forward) | 28.41 |
| 价格/销量 (P/S) | 3.04 |
| 股市价格/股市净资产 (P/B) | 1.04 |
| 52周波幅 | |
| 利润日期 | 30 Apr 2026 |
| 营业毛利率 | -85.16% |
| 营业利益率 (TTM) | 9.72% |
| 稀释每股收益 (EPS TTM) | -76.53 |
| 季度收入增长率 (YOY) | -4.20% |
| 季度盈利增长率 (YOY) | -83.30% |
| 总债务/股东权益 (D/E MRQ) | 20.50% |
| 流动比率 (MRQ) | 5.99 |
| 营业现金流 (OCF TTM) | 515.30 M |
| 杠杆自由现金流 (LFCF TTM) | 250.23 M |
| 资产报酬率 (ROA TTM) | 1.55% |
| 股东权益报酬率 (ROE TTM) | -27.52% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Medical Devices (US) | 混合的 | 看跌 |
| Medical Devices (全球的) | 混合的 | 看跌 | |
| 股票 | Bio-Rad Laboratories, Inc. | 混合的 | 看跌 |
AIStockmoo 评分
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 2.0 |
| 平均 | 0.00 |
|
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (56% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (44% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (42% of 2023 sales), Europe (31%), Asia (31%), and other (6%). Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing. |
|
| 部门 | Healthcare |
| 行业 | Medical Devices |
| 投资方式 | Small Core |
| 内部持股比例 | 16.14% |
| 机构持股比例 | 93.04% |
该时间范围内无数据。
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| EDWARDS JEFFREY L | - | - | 0 | 0 |
| HINCKLEY GREG K | - | - | 0 | 0 |
| PEI MELINDA LITHERLAND | - | - | 0 | 0 |
| PINKSTON ARNOLD A | - | - | 0 | 0 |
| 累积净数量 | 0 | |||
| 累积净值 ($) | 0 | |||
| 累积平均购买 ($) | - | |||
| 累积平均卖出 ($) | - | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| PINKSTON ARNOLD A | 董事 | 21 Apr 2026 | 执行期权 | 407 | - | - |
| EDWARDS JEFFREY L | 董事 | 21 Apr 2026 | 执行期权 | 407 | - | - |
| PEI MELINDA LITHERLAND | 董事 | 21 Apr 2026 | 执行期权 | 407 | - | - |
| HINCKLEY GREG K | 董事 | 21 Apr 2026 | 执行期权 | 407 | - | - |
支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。
投资组合